Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTUS intradialytic parenteral nutrition study in chronic hemodialysis patients
2025-522111-42-02Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Intradialytic Parenteral Nutrition (Fresenius Kabi) in chronic kidney disease (CKD) and Muscle protein turnover disorder (2 arms), sponsored by Erasmus MC. Primary endpoint: Difference in myofibrillar fractional synthetic rate during a one-week treatment with IDPN versus control. Planned start Oct 2025; status: authorised.
02
Drugs
Intradialytic Parenteral Nutrition (Fresenius Kabi)
03
Conditions
chronic kidney disease (CKD)Muscle protein turnover disorder
Beyond the preview
Go deeper on 2025-522111-42-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522111-42-02.